Trivalent CAR-T has been investigated, for example, for GBM patients, and the development of trivalent CAR-T cells (targeting both HER2, IL-13Rα2 and EphA2) can overcome antigenic heterogeneity and improve treatment outcomes. Here, EPHA2 is linked to glioblastoma.